Support The Moscow Times!

Drugmaker Plans IPO

Pharmsynthez plans to raise 500 million rubles ($16.3 million) in a stock market float this November, delivering a rare boost to the country’s flagging IPO market, the pharmaceutical company said Monday.

The funds will be used to build a new production plant in St. Petersburg and make strategic acquisitions overseas, the company said in a statement.

“There is enormous potential for growth in innovative medicine production in Russia, and Pharmsynthez is extremely well placed to capitalize on that growth,” chief executive Dmitry Genkin, who owns 25 percent, said in a statement.

A source familiar with the deal said about a 30 percent stake in the group could be floated.


Read more

Independent journalism isn’t dead. You can help keep it alive.

The Moscow Times’ team of journalists has been first with the big stories on the coronavirus crisis in Russia since day one. Our exclusives and on-the-ground reporting are being read and shared by many high-profile journalists.

We wouldn’t be able to produce this crucial journalism without the support of our loyal readers. Please consider making a donation to The Moscow Times to help us continue covering this historic time in the world’s largest country.